Case report: bullous pemphigoid development underlies dystrophic epidermolysis bullosa disease worsening

Front Immunol. 2022 Jul 29:13:929286. doi: 10.3389/fimmu.2022.929286. eCollection 2022.

Abstract

Autoimmune response to cutaneous basement membrane components superimposed on a genetic skin fragility disease, hereditary epidermolysis bullosa (EB), has been described, but its effects on disease course remain unclear. We report a 69-year-old individual with congenital skin fragility and acral trauma-induced blistering that had suddenly worsened with the onset of severe itch and diffuse spontaneous inflammatory blisters. Next-generation sequencing identified compound heterozygous null and missense COL7A1 mutations, allowing the diagnosis of recessive dystrophic EB. However, the patient's clinical history prompted us to investigate whether he might have developed a pathological autoimmune response against basement membrane components. Tissue-bound and circulating IgG antibodies to the major bullous pemphigoid (BP) antigen, BP180, were detected in the patient's skin and serum, respectively, consistent with a diagnosis of BP. Corticosteroid therapy was initiated resulting in remission of BP manifestations. EB patients presenting rapid disease worsening should be investigated for the development of a concomitant autoimmune blistering disease.

Keywords: autoimmunity; collagen VII; disease severity and modifiers; genodermatosis; pemphigoids.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Autoimmune Diseases* / pathology
  • Blister / pathology
  • Collagen / genetics
  • Collagen Type VII / genetics
  • Epidermolysis Bullosa Dystrophica* / complications
  • Epidermolysis Bullosa Dystrophica* / diagnosis
  • Epidermolysis Bullosa Dystrophica* / genetics
  • Humans
  • Male
  • Pemphigoid, Bullous* / diagnosis
  • Pemphigoid, Bullous* / drug therapy
  • Skin

Substances

  • COL7A1 protein, human
  • Collagen Type VII
  • Collagen